Personalized medicine modality based on patient-derived xenografts from a malignant transformed GCTB harboring H3F3A G34W mutation.

ABSTRACT:

Background

The function of H3F3A G43W mutation, which has been observed in almost all GCTB, remains poorly characterized. Breakthrough in malignant GCTB has been trapped by the lack of clinical available drugs, limited canonical patient samples and paucity of fidelity preclinical models.

Methods

Tumor samples obtained from a malignant GCTB was implanted in immunodeficient mice for the generation of PDX. Histological examination and short tandem repeat (STR) were used for inherited features analyses. An epigenetic/transcriptional targeted compound library was selected for drug screening. The in vivo effects of selected drug were validated in PDX model.

Results

We established the PDX model with recurrent malignant GCTB specimens, histological examination and STR analyse

SUBMITTER: Yafei J 

PROVIDER: S-EPMC8173097 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature